Processa Pharmaceuticals (PCSA) Competitors $1.15 -0.01 (-0.86%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PCSA vs. NERV, HCWB, TLPH, CMMB, TRIB, SYBX, TENX, BIOR, AIM, and IPAShould you be buying Processa Pharmaceuticals stock or one of its competitors? The main competitors of Processa Pharmaceuticals include Minerva Neurosciences (NERV), HCW Biologics (HCWB), Talphera (TLPH), Chemomab Therapeutics (CMMB), Trinity Biotech (TRIB), Synlogic (SYBX), Tenax Therapeutics (TENX), Biora Therapeutics (BIOR), AIM ImmunoTech (AIM), and ImmunoPrecise Antibodies (IPA). These companies are all part of the "pharmaceutical products" industry. Processa Pharmaceuticals vs. Minerva Neurosciences HCW Biologics Talphera Chemomab Therapeutics Trinity Biotech Synlogic Tenax Therapeutics Biora Therapeutics AIM ImmunoTech ImmunoPrecise Antibodies Processa Pharmaceuticals (NASDAQ:PCSA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation. Which has more risk and volatility, PCSA or NERV? Processa Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Is PCSA or NERV more profitable? Minerva Neurosciences' return on equity of 0.00% beat Processa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Processa PharmaceuticalsN/A -151.09% -130.16% Minerva Neurosciences N/A N/A -62.06% Does the media favor PCSA or NERV? In the previous week, Minerva Neurosciences had 1 more articles in the media than Processa Pharmaceuticals. MarketBeat recorded 4 mentions for Minerva Neurosciences and 3 mentions for Processa Pharmaceuticals. Minerva Neurosciences' average media sentiment score of 0.40 beat Processa Pharmaceuticals' score of -1.50 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Processa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Negative Minerva Neurosciences 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, PCSA or NERV? Minerva Neurosciences is trading at a lower price-to-earnings ratio than Processa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProcessa PharmaceuticalsN/AN/A-$11.12M-$3.39-0.34Minerva NeurosciencesN/AN/A-$30M-$4.44-0.59 Does the MarketBeat Community believe in PCSA or NERV? Minerva Neurosciences received 333 more outperform votes than Processa Pharmaceuticals when rated by MarketBeat users. However, 58.33% of users gave Processa Pharmaceuticals an outperform vote while only 58.32% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformProcessa PharmaceuticalsOutperform Votes1458.33% Underperform Votes1041.67% Minerva NeurosciencesOutperform Votes34758.32% Underperform Votes24841.68% Do institutionals & insiders have more ownership in PCSA or NERV? 91.9% of Processa Pharmaceuticals shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 13.0% of Processa Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate PCSA or NERV? Processa Pharmaceuticals presently has a consensus price target of $6.00, indicating a potential upside of 421.74%. Minerva Neurosciences has a consensus price target of $5.00, indicating a potential upside of 90.84%. Given Processa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Processa Pharmaceuticals is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Processa Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryProcessa Pharmaceuticals beats Minerva Neurosciences on 10 of the 15 factors compared between the two stocks. Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get Processa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricProcessa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.76M$7.02B$5.40B$8.53BDividend YieldN/A7.97%5.15%4.14%P/E Ratio-0.299.53113.7615.14Price / SalesN/A385.111,483.0493.53Price / CashN/A47.3339.7134.04Price / Book0.285.324.665.01Net Income-$11.12M$153.56M$119.06M$225.46M7 Day Performance-12.21%0.12%0.79%0.37%1 Month Performance-13.53%15.23%5.65%3.57%1 Year Performance-83.14%41.16%36.80%29.42% Processa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAProcessa Pharmaceuticals2.348 of 5 stars$1.15-0.9%$6.00+421.7%-83.8%$3.76MN/A-0.2920News CoverageNegative NewsNERVMinerva Neurosciences4.0737 of 5 stars$2.46+0.8%$5.00+103.3%-47.6%$17.20MN/A-0.559Upcoming EarningsAnalyst ForecastNews CoverageHCWBHCW Biologics1.1279 of 5 stars$0.45-2.5%N/A-73.0%$17.06M$3.92M-0.4340Short Interest ↓Gap UpTLPHTalphera2.4262 of 5 stars$1.00+2.7%$4.50+350.0%N/A$16.99M$398,000.00-1.5619Gap DownCMMBChemomab Therapeutics2.5672 of 5 stars$1.53+6.3%$5.67+270.4%+89.0%$16.91MN/A-1.3420Gap DownTRIBTrinity Biotech0.7 of 5 stars$2.20+14.0%N/A-24.6%$16.76M$56.83M-0.81480Gap UpSYBXSynlogic2.7858 of 5 stars$1.42flat$30.00+2,012.7%-16.6%$16.62M$3.17M-0.2180News CoveragePositive NewsTENXTenax Therapeutics3.2034 of 5 stars$4.87+2.5%$170.67+3,404.4%-69.7%$16.61MN/A0.009News CoverageBIORBiora Therapeutics3.3416 of 5 stars$4.42+13.3%$150.00+3,293.7%-83.3%$16.27MN/A-0.08120News CoverageHigh Trading VolumeAIMAIM ImmunoTech1.3085 of 5 stars$0.27+1.1%$3.00+1,011.1%-43.7%$15.84M$200,000.00-0.4720High Trading VolumeIPAImmunoPrecise Antibodies2.5622 of 5 stars$0.58-15.1%$6.00+942.0%-80.3%$15.72M$18.16M-0.7480Gap DownHigh Trading Volume Related Companies and Tools Related Companies Minerva Neurosciences Alternatives HCW Biologics Alternatives Talphera Alternatives Chemomab Therapeutics Alternatives Trinity Biotech Alternatives Synlogic Alternatives Tenax Therapeutics Alternatives Biora Therapeutics Alternatives AIM ImmunoTech Alternatives ImmunoPrecise Antibodies Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PCSA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Processa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
